Overview
Pellicarnos develops food for special medical purposes (FSMP) for patients who need metabolic support in clinical and home settings. The company offers Pellicar-F, a formula that supports healing of pressure sores and chronic wounds, and conducts research aimed at reducing the risk of pulmonary complications after surgery. Its products are developed with academic and clinical partners and are validated in laboratory and clinical testing.
Financials
The financial statement for 2025 has not yet been filed with the Financial Document Repository (past deadline).
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2024.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2022-12-01. Active
69 1140 2105 0000 4834 3800 1001
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Public aid
6 public aid cases recorded, with a total value of $557,956.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Feb 25, 2026 | Aid for research and development projects: experimental development | –– | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Feb 25, 2026 | Aid for research and development projects: industrial research | –– | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Feb 25, 2026 | Aid for SME participation in trade fairs | –– | Dyrektor Narodowego Centrum Badań i Rozwoju |
Tenders
No recorded participation in tenders.
Trademarks
Pellicarnos holds 1 active trademark registered with the Polish Patent Office. The first mark was filed in 2023.
| Mark | Protected until | |
|---|---|---|
| PelliCarnos(word) | May 18, 2033 |
Authorized Representatives
Manner of representation
Two members of the management board acting jointly, or one member of the management board acting jointly with a commercial proxy, are authorized to make declarations of will and sign on behalf of the company.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Proper Medical Writingsp. z o.o. | $514,848.41 | propermedicalwriting.com | ||
| PolbionicaS.A. | $356,011.70 | polbionica.com | ||
| BiocamS.A. | $327,799.68 | biocam.ai | ||
| Medicofarma BiotechS.A. | $314,882.33 | medicofarmabiotech.pl | ||
| FcbiotechS.A. | $246,877.92 | fcbiotech.pl | ||
| Oncotarget Wojciech JurczakS.K.A. | $192,291.27 | oncotarget.pl | ||
| Sfpesp. z o.o. | $72,850.26 | sfpe.co.pl | ||
| Biostat Research and Developmentsp. z o.o. | $50,225.77 | biostat.com.pl | ||
| Zawamedsp. z o.o. | $43,909.06 | zawamed.pl | ||
| Stenocoatsp. z o.o. | $36,665.21 | stenocoat.com |
Change history
| Date | Event | |
|---|---|---|
| 2024-08-22 | Share capital change (100,000.00 PLN → 110,000.00 PLN) | |
| 2022-11-14 | Entered in the register |
FAQ
Last updated: 2026-10-03